Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108704 | 0.90 | CYP3A4 (0.37) | CYP3A4AVPR1AHCAR2HSD11B1NR1I2 | |
| SCHEMBL1108715 | 0.90 | CYP3A4 (0.39) | CYP3A4AVPR1AHCAR2HSD11B1OPRD1 | |
| SCHEMBL1108703 | 0.86 | CYP3A4 (0.37) | CYP3A4AVPR1AHCAR2OPRD1HSD17B10 | |
| SCHEMBL1108721 | 0.86 | HSD11B1 (0.39) | CYP3A4HSD11B1NR1I2OPRD1CCNC | |
| SCHEMBL1108711 | 0.86 | CYP3A4 (0.36) | CYP3A4AVPR1AHCAR2OPRD1 | |
| SCHEMBL1108709 | 0.86 | CYP3A4 (0.36) | CYP3A4AVPR1AHCAR2OPRD1 | |
| SCHEMBL1108712 | 0.82 | HSD11B1 (0.43) | HSD11B1NR1I2 | |
| SCHEMBL1108717 | 0.80 | ADRB2 (0.41) | CYP3A4HSD11B1NR1I2CCNCCDK8 | |
| SCHEMBL1108728 | 0.79 | OPRD1 (0.43) | CYP3A4AVPR1AHCAR2HSD11B1OPRD1 | |
| SCHEMBL1108706 | 0.78 | HSD11B1 (0.44) | HSD11B1NR1I2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | HSD11B1, HSD17B1, HSD17B3 | CYP3A4 63/4885AVPR1A 1852/4885HCAR2 754/4885 |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | GPR119, CYP11B2, CYP11B1 | CYP3A4 39/4885AVPR1A 2351/4885HCAR2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.